Public Sector Pension Investment Board Purchases 865 Shares of IDEXX Laboratories, Inc. $IDXX

Public Sector Pension Investment Board boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.1% during the 3rd quarter, HoldingsChannel reports. The firm owned 7,005 shares of the company’s stock after purchasing an additional 865 shares during the period. Public Sector Pension Investment Board’s holdings in IDEXX Laboratories were worth $4,475,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Blalock Williams LLC bought a new stake in IDEXX Laboratories during the third quarter valued at approximately $590,000. New York State Common Retirement Fund boosted its stake in shares of IDEXX Laboratories by 6.8% during the 3rd quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after acquiring an additional 3,820 shares during the last quarter. Arkadios Wealth Advisors purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth $405,000. Mediolanum International Funds Ltd grew its position in shares of IDEXX Laboratories by 14.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock valued at $24,441,000 after acquiring an additional 4,909 shares during the period. Finally, Principal Financial Group Inc. increased its stake in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock worth $840,638,000 after purchasing an additional 187,967 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on IDXX. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 7th. Leerink Partners set a $785.00 price objective on IDEXX Laboratories in a research report on Monday, November 3rd. Piper Sandler reduced their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. JPMorgan Chase & Co. raised their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Finally, Barclays lowered their price target on shares of IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $783.33.

IDEXX Laboratories Stock Down 0.7%

Shares of IDXX opened at $630.73 on Friday. The business’s 50 day moving average is $679.11 and its 200 day moving average is $669.15. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $769.98. The company has a market capitalization of $50.36 billion, a PE ratio of 48.26, a price-to-earnings-growth ratio of 3.86 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 earnings per share for the quarter, missing the consensus estimate of $2.93 by ($0.01). The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.53 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the sale, the executive vice president owned 9,823 shares in the company, valued at approximately $6,352,730.56. The trade was a 53.60% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 18,180 shares of company stock valued at $11,626,996. Corporate insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.